Aethlon Medical, Inc. (OTCQB: AEMD) creates affinity
biofiltration devices to treat life-threatening diseases. The company’s leading
therapeutic candidate, the Aethlon Hemopurifier®, is a broad-spectrum
therapeutic strategy developed to address drug resistant viral pathogens. To
date, the device, which was recently named among ‘The 11 Most Remarkable
Advances in Healthcare’ by Time Magazine, has been successfully administered to
individuals infected with Ebola virus, hepatitis C and the human
immunodeficiency virus (HIV), demonstrating the immense potential for the
company’s novel treatment device moving forward.
In addition to validating the treatment of some of the
world’s deadliest pathogens, Aethlon is also investigating the use of its
Hemopurifier therapy to capture tumor-derived exosomes, which have been shown
to promote cancer progression. When complete, this application will address a
substantial demand within the cancer treatment market. In April, the company
took a significant step toward the eventual commercialization of its
proprietary therapeutic candidate by entering into a clinical trial agreement
with the University of California, Irvine to establish baseline exosome levels
and monitor their associations with various types of cancers. The results of
this study will help direct future clinical investigations.
The company’s current product pipeline is built upon its
revolutionary Aethlon ADAPT™ system, which is an adaptive dialysis-like
affinity platform technology that provides the foundation for a new class of
therapeutics that target the selective clearance of harmful agents from the
circulatory system. In addition to the Hemopurifier, Aethlon is currently
utilizing this system to develop HER2osome™ to target HER2+ breast cancer and a
novel medical device to reduce the incidence of sepsis in combat-injured
soldiers, which is sponsored by the Defense Advanced Research Projects Agency
(DARPA).
Exosome Sciences, Inc., Aethlon’s majority-owned subsidiary,
is supporting this product development through the creation of its
groundbreaking diagnostic tool, ELLSA™. This device provides greater exosome
detection sensitivity than any other product currently on the marketplace. With
ELLSA, Aethlon gains enhanced ability to identify and quantify the underlying
presence of exosomes in a wide variety of relevant treatment applications.
As Aethlon continues to develop its unique pipeline of
therapeutic solutions, the potential for market growth upon commercialization
is effectively limitless. With a potential uplisting to the NASDAQ Capital
Markets currently pending approval, it is an exciting time for shareholders of
this company.
For more information, visit www.aethlonmedical.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment